Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540359 | 0.95 | KAT8 (0.48) | PLAUESR1KAT8PPARA | |
| SCHEMBL14613741 | 0.94 | KAT8 (0.50) | ESR1KAT8PPARA | |
| SCHEMBL5541800 | 0.90 | CNR1 (0.52) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL3359160 | 0.82 | CYP1A2 (0.53) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL10523809 | 0.81 | KAT8 (0.50) | ESR1KAT8PPARA | |
| SCHEMBL5542991 | 0.80 | TRPV1 (0.43) | HPGDTRPV1CYP1A2 | |
| SCHEMBL5677501 | 0.80 | NPC1 (0.49) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL22288362 | 0.79 | CYP1A2 (0.51) | TRPV1CYP1A2PTPN1 | |
| SCHEMBL22644829 | 0.79 | PLAU (0.46) | PLAUHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL13496276 | 0.78 | PLAU (0.42) | PLAUHSD17B1HSD17B2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2557103-B1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DAINIPPON INK & CHEMICALS (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8519065-B2 | Epoxy compound, curable composition, and cured product thereof | DIC CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20130144030-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DIC CORPORATION (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2557103-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | DIC Corporation (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NPC1 2404/4885HPGD 3159/4885MAPK1 1392/4885 |
| US-20130144030-A1 | EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF | HEATR1, EEF1A1, EPN1 | NPC1 3746/4885HPGD 1236/4885MAPK1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.